DFSP: Mohs as Treatment of Choice (NCCN v2.2026)

Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive soft tissue tumor of fibroblastic origin classified as an intermediate (rarely metastasizing) neoplasm by the WHO. The incidence is approximately 0.8-5 per million per year, making it one of the most common dermal sarcomas but still a rare tumor overall. DFSP typically presents in young to middle-aged adults (peak incidence 20-50 years) with no strong sex predilection, though some series report a slight male predominance. The trunk is the most common site (40-50%), followed by the proximal extremities (30-40%) and the head and neck (10-15%). DFSP is characterized by a pathognomonic chromosomal translocation. T(17;22)(q22;q13). That creates the COL1A1::PDGFB fusion gene, present in over 90% of cases. This fusion results in constitutive activation of platelet-derived growth factor receptor (PDGFR), driving tumor proliferation, and serves as the basis for targeted therapy with imatinib. Despite its locally aggressive behavior with extensive subclinical extension, classic DFSP has a very low metastatic potential (<5%), making local control with complete margin assessment the cornerstone of management.

DFSP typically presents as a slowly growing, indurated, firm plaque or nodule in the dermis and subcutis. The surface may be skin-colored, pink, red-brown, or violaceous, and the lesion often has a protuberant (raised, bumpy) quality that develops as the tumor enlarges over months to years. One of the most clinically significant features of DFSP is how frequently it is misdiagnosed. Common initial misdiagnoses include hypertrophic scar, keloid, dermatofibroma, lipoma, cyst, and morphea. Many patients report having the lesion for years before the correct diagnosis is established, as the slow growth rate does not raise immediate clinical concern. The tumor may grow for years as an asymptomatic plaque before developing more rapidly enlarging nodular components. Diagnosis requires a deep biopsy. A superficial shave biopsy is inadequate because it may only sample the overlying dermis without capturing the diagnostic spindle cell infiltrate in the deeper dermis and subcutis. A deep punch biopsy (at least 4-6 mm) or incisional biopsy extending into the subcutaneous fat is essential. Immunohistochemistry is confirmatory: DFSP is CD34-positive and factor XIIIa-negative, which distinguishes it from dermatofibroma (CD34-negative, factor XIIIa-positive). FISH for the COL1A1::PDGFB translocation or RT-PCR provides molecular confirmation and is important for treatment planning, particularly if imatinib therapy may be considered.

Several histologic variants of DFSP are recognized beyond classic DFSP and FS-DFSP. The Bednar tumor (pigmented DFSP) contains dendritic melanocytes scattered within the spindle cell proliferation, giving the tumor a dark pigmented appearance that can mimic melanoma clinically. Bednar tumors account for approximately 1-5% of DFSP cases and are more common in Black patients. The myxoid variant of DFSP shows prominent myxoid stromal change, which can lead to misdiagnosis as a myxoid soft tissue tumor. The atrophic (plaquelike) variant presents as a depressed or atrophic plaque rather than the typical protuberant morphology, making clinical recognition even more difficult. Giant cell fibroblastoma is considered the juvenile form of DFSP, presenting in children and characterized by pseudovascular spaces lined by giant cells. It shares the same COL1A1::PDGFB translocation as DFSP and has similar biologic behavior with excellent prognosis after complete excision. All DFSP variants share the same fundamental surgical management principle: complete margin assessment with Mohs/PDEMA is preferred to ensure local control.

DFSP is characterized by a monotonous proliferation of spindle-shaped fibroblastic cells arranged in a storiform (cartwheel or pinwheel) pattern. This storiform architecture is one of the most recognizable histologic patterns in dermatopathology. The tumor infiltrates the subcutaneous fat in a characteristic "honeycomb" or "lace-like" pattern, where tumor cells surround individual fat lobules and extend between adipocytes, creating finger-like projections that extend far beyond the clinically apparent tumor margin. This infiltrative growth pattern is the primary reason that DFSP has such extensive subclinical extension and why wide margins or complete margin assessment (Mohs/PDEMA) is essential. The irregular, tentacle-like deep extensions make clinical margin estimation extremely unreliable. Subclinical extension of 3 cm or more beyond the clinically visible tumor is not uncommon. The tumor typically involves the full thickness of the dermis and extends into the subcutaneous fat, but can also invade underlying fascia and muscle in advanced cases. Mitotic activity is generally low in classic DFSP.

NCCN v2.2026 guidelines for DFSP establish Mohs micrographic surgery (the most commonly used form of PDEMA) as the recommended surgical approach for DFSP. This is one of the strongest endorsements of Mohs in the NCCN guidelines for any tumor type. Mohs is not merely listed as an alternative but as the preferred technique when available. The rationale is compelling: DFSP has extensive, irregular, and unpredictable subclinical extension that makes clinical margin estimation unreliable, and Mohs/PDEMA provides complete peripheral and deep margin assessment that accounts for these irregular extensions. Published recurrence rates after Mohs for DFSP are approximately 1-3%, compared to 7-20% after wide local excision, even with 2-4 cm margins. Tissue conservation is an additional advantage, as wide excision with 2-4 cm margins on the trunk or extremities produces very large defects that may require complex reconstruction or skin grafting.

In some DFSP cases, complete en face margin assessment may not be achievable due to anatomical constraints. Deep margin structures such as major vessels, nerves, periosteum, or bone may preclude the surgeon from taking tissue for en face evaluation without causing unacceptable morbidity. In these situations, the Mohs surgeon achieves clear margins on the peripheral and accessible deep margins, but a portion of the deep margin remains non-visualized. NCCN v2.2026 recommends multidisciplinary discussion for cases where complete margin assessment cannot be achieved. Options include close clinical and imaging surveillance of the non-visualized area, adjuvant radiation therapy to the area of uncertain margin status, or surgical re-excision by a surgical oncologist or orthopedic oncologist who can address the deep structures. The decision depends on the specific anatomy involved, the patient's overall risk profile, and the availability of adjuvant modalities. Documentation of which specific margin areas were not fully assessed is essential for guiding subsequent management and surveillance.

The role of adjuvant radiation therapy in DFSP is more limited than in MCC and is guided by margin status and surgical approach. When Mohs/PDEMA achieves complete negative margins, adjuvant RT is NOT recommended by NCCN. The local recurrence rate with Mohs alone is sufficiently low (1-3%) that RT provides no additional benefit and exposes the patient to unnecessary radiation morbidity. When Mohs/PDEMA is NOT used and the patient is treated with standard excision, NCCN v2.2026 recommends consideration of RT if margins are narrow (close but negative) and further re-resection is not feasible upon recurrence. This updated wording in v2.2026 reflects a selective approach: RT is not routinely indicated after negative-margin wide excision, but should be considered when the margins are close and surgical re-excision options are limited (e.g., anatomically constrained sites). For positive margins after excision, the preferred approach is re-resection if feasible. If re-resection is not possible, RT to the positive margin area is recommended. RT for DFSP is typically delivered as external beam radiation to the tumor bed with appropriate margins.

For DFSP that is unresectable (due to size, location, or extent of local invasion) or has metastasized, imatinib mesylate (Gleevec) is the NCCN-recommended systemic therapy. Imatinib is a tyrosine kinase inhibitor that targets the PDGFR signaling pathway constitutively activated by the COL1A1::PDGFB fusion protein. Response rates to imatinib in COL1A1::PDGFB-positive DFSP are approximately 50-70%, with some patients achieving sufficient tumor shrinkage to convert an initially unresectable tumor to a resectable one (neoadjuvant use). Confirmation of the COL1A1::PDGFB translocation by FISH or RT-PCR is essential before initiating imatinib therapy, as tumors lacking this translocation (rare) are unlikely to respond. The standard dose is 400 mg twice daily (800 mg/day), though some protocols start at 400 mg once daily. Duration of treatment varies. For unresectable disease, treatment is continued until disease progression or unacceptable toxicity. Common side effects include periorbital edema, nausea, diarrhea, fatigue, and cytopenias. Patients with FS-DFSP may have a lower response rate to imatinib, as the fibrosarcomatous component may not harbor the translocation or may have acquired additional oncogenic drivers.

Fibrosarcomatous DFSP (FS-DFSP) deserves special emphasis because it represents a biologically distinct and more aggressive variant that requires modified management. FS-DFSP is identified when areas of the tumor show transition from the classic low-grade storiform pattern to a high-grade fibrosarcomatous pattern characterized by herringbone fascicular arrangement, increased mitotic activity (>5 mitoses per 10 high-power fields), and greater nuclear atypia. FS transformation is found in approximately 10-15% of all DFSP cases and may be present de novo or develop in recurrent tumors. The critical clinical distinction is that FS-DFSP carries a significantly higher risk of both local recurrence and distant metastasis compared to classic DFSP. Metastatic rates for FS-DFSP are reported at 10-15%, with the lungs being the most common site of distant spread. When FS-DFSP is identified, staging workup should include CT of the chest to evaluate for pulmonary metastases. Referral to a sarcoma center is recommended for multidisciplinary evaluation and treatment planning. Surgical excision should aim for wider margins, and the threshold for adjuvant radiation therapy is lower than for classic DFSP. Close postoperative surveillance with serial clinical examinations and periodic chest imaging is warranted.

Several clinical scenarios require special consideration in DFSP management. Pregnancy has been reported to accelerate DFSP growth, likely mediated by hormonal effects on PDGFR signaling. Pregnant patients with DFSP may notice rapid tumor enlargement, and definitive surgical treatment should be planned postpartum when possible, though growing tumors may require earlier intervention. DFSP arising at sites of prior radiation therapy has been described, typically with a latency period of 10-20 years. Radiation-associated DFSP has similar biologic behavior to sporadic DFSP and should be managed with the same surgical principles. Recurrent DFSP (after prior incomplete excision) may be more difficult to clear surgically due to scar tissue making frozen section interpretation challenging, and the recurrence may harbor areas of fibrosarcomatous transformation. Thorough histologic evaluation of the recurrence specimen is essential. Pediatric DFSP (including giant cell fibroblastoma) is generally managed with the same surgical principles as adult DFSP, with particular emphasis on tissue conservation in growing children.

The prognosis for classic DFSP is generally favorable when treated with appropriate surgery providing complete margin assessment. Local recurrence rates after Mohs/PDEMA are approximately 1-3%, making it the treatment with the best documented local control. Wide local excision with adequate margins (2-4 cm) has local recurrence rates of 7-20%, reflecting the challenge of predicting subclinical extension clinically. Metastasis from classic DFSP is rare (<5%), and disease-specific mortality is low. However, FS-DFSP has a substantially worse prognosis with higher local recurrence and metastatic rates. Follow-up for classic DFSP consists of clinical examination of the surgical site and regional lymph nodes every 6-12 months. Physical examination is usually sufficient, but MRI of the surgical site should be considered when clinical examination is insufficient to assess for deep recurrence, particularly in areas with significant postoperative changes or complex reconstruction. For FS-DFSP, more frequent follow-up (every 3-6 months for the first 2-3 years) and periodic chest imaging is recommended. There is no established role for routine systemic imaging in classic DFSP. Patients should be counseled that recurrences can occur late (beyond 5 years), and lifelong periodic surveillance is reasonable.